Chongqing Zhifei Biological Products Co., Ltd.

SZSE:300122 Voorraadrapport

Marktkapitalisatie: CN¥68.7b

Chongqing Zhifei Biological Products Toekomstige groei

Future criteriumcontroles 4/6

Chongqing Zhifei Biological Products is forecast to grow earnings and revenue by 49.6% and 17.3% per annum respectively. EPS is expected to grow by 47.8% per annum. Return on equity is forecast to be 19.2% in 3 years.

Belangrijke informatie

49.6%

Groei van de winst

47.8%

Groei van de winst per aandeel

Biotechs winstgroei44.8%
Inkomstengroei17.3%
Toekomstig rendement op eigen vermogen19.2%
Dekking van analisten

Good

Laatst bijgewerkt01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Sep 30
Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Sep 03
Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be

Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

Aug 23
Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)

We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Jul 26
We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt

Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

May 21
Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E

Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Apr 26
Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts

Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Mar 26
Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?

Winst- en omzetgroeiprognoses

SZSE:300122 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202650,14710,27711,07210,2439
12/31/202553,33510,3246,7388,69013
12/31/202432,2013,3121,98613,5252
9/30/202436,4323,6902,3313,346N/A
6/30/202446,7316,0445,5006,512N/A
3/31/202453,1417,4964,6655,763N/A
12/31/202352,9188,0707,8628,996N/A
9/30/202349,7128,4622,4763,586N/A
6/30/202344,3568,0704,3575,546N/A
3/31/202340,5967,6482,9514,266N/A
1/1/202338,2647,5395361,989N/A
9/30/202236,6477,412-3601,175N/A
6/30/202235,8358,447-1,151596N/A
3/31/202235,56711,1933,4525,305N/A
12/31/202130,65210,2096,5758,508N/A
9/30/202125,9699,2267,5159,350N/A
6/30/202121,3687,2878,0509,627N/A
3/31/202116,4823,7232,6913,868N/A
12/31/202015,1903,3012,6703,497N/A
9/30/202013,9713,0822,5543,272N/A
6/30/202012,5422,7241,0381,604N/A
3/31/202010,9282,3816911,318N/A
12/31/201910,5872,3667941,367N/A
9/30/20199,4002,1285981,145N/A
6/30/20198,1951,916247764N/A
3/31/20196,6841,694-42282N/A
12/31/20185,2281,451106586N/A
9/30/20184,0681,234-32698N/A
6/30/20182,969943N/A170N/A
3/31/20182,019632N/A298N/A
12/31/20171,343432N/A204N/A
9/30/2017942311N/A207N/A
6/30/2017707192N/A126N/A
3/31/201746434N/A87N/A
12/31/201644633N/A90N/A
9/30/201643144N/A253N/A
6/30/2016512101N/A207N/A
3/31/2016660209N/A265N/A
12/31/2015713197N/A223N/A
9/30/2015779172N/A143N/A
6/30/2015805160N/A165N/A
3/31/2015835153N/A167N/A
12/31/2014801148N/A161N/A
9/30/2014777136N/A153N/A
6/30/2014735124N/A179N/A
3/31/2014758132N/A157N/A
12/31/2013780130N/A222N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 300122's forecast earnings growth (49.6% per year) is above the savings rate (2.9%).

Winst versus markt: 300122's earnings (49.6% per year) are forecast to grow faster than the CN market (25.8% per year).

Hoge groeiwinsten: 300122's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: 300122's revenue (17.3% per year) is forecast to grow faster than the CN market (14% per year).

Hoge groei-inkomsten: 300122's revenue (17.3% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 300122's Return on Equity is forecast to be low in 3 years time (19.2%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y